BR0207058A - Method for reducing transfusion-associated disease and plasma adverse effects to increase the purity and safety of multiple blood-derived components, enriched cryoprecipitate, cryo-depleted plasma, and fibrin glue - Google Patents

Method for reducing transfusion-associated disease and plasma adverse effects to increase the purity and safety of multiple blood-derived components, enriched cryoprecipitate, cryo-depleted plasma, and fibrin glue

Info

Publication number
BR0207058A
BR0207058A BR0207058-8A BR0207058A BR0207058A BR 0207058 A BR0207058 A BR 0207058A BR 0207058 A BR0207058 A BR 0207058A BR 0207058 A BR0207058 A BR 0207058A
Authority
BR
Brazil
Prior art keywords
plasma
safety
blood
purity
adverse effects
Prior art date
Application number
BR0207058-8A
Other languages
Portuguese (pt)
Inventor
Edward Shanbrom
Original Assignee
Shanbrom Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/778,681 external-priority patent/US6541518B2/en
Application filed by Shanbrom Tech Llc filed Critical Shanbrom Tech Llc
Publication of BR0207058A publication Critical patent/BR0207058A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0215—Disinfecting agents, e.g. antimicrobials for preserving living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/36—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Dentistry (AREA)
  • Communicable Diseases (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MéTODO PARA REDUZIR DOENçA ASSOCIADA COM TRANSFUSãO E EFEITOS ADVERSOS NO PLASMA E PARA AUMENTAR A PUREZA E SEGURANçA DE MúLTIPLOS COMPONENTES DERIVADOS DE SANGUE, CRIOPRECIPITADO ENRIQUECIDO, PLASMA CRIO-EXAURIDO, E, COLA DE FIBRINA". A coleta, processamento e transferência de sangue por separação de componentes distintos, contendo citrato adicional em uma ou outra bolsa de coleta ou processamento, provê aumentada produção de impurezas de crioprecipitado. Inibindo-se a ativação ou desnaturação dos componentes sang³íneos, incluindo células sang³íneas e proteínas de plasma, e com a remoção dos componentes ativados e desnaturados, é conseguida, desse modo, a segurança e eficácia dos produtos finais, que incluem cola de fibrina."METHOD FOR REDUCING BLOOD DISEASE ASSOCIATED DISEASE AND ADVERSE EFFECTS ON PLASMA AND TO INCREASE THE PURITY AND SAFETY OF MULTIPLE BLOOD, CRYOPRECINATED, CRYRIN, COLA, CRYRINE AND PLASMA CRYRINE-EXA PLASMA The collection, processing and transfer of blood by separation of distinct components containing additional citrate in either collection or processing pouch provides increased production of cryoprecipitate impurities. By inhibiting the activation or denaturation of blood components, including blood cells and plasma proteins, and by removing the activated and denatured components, the safety and efficacy of end products including fibrin glue are thus achieved.

BR0207058-8A 2001-02-07 2002-02-07 Method for reducing transfusion-associated disease and plasma adverse effects to increase the purity and safety of multiple blood-derived components, enriched cryoprecipitate, cryo-depleted plasma, and fibrin glue BR0207058A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/778,681 US6541518B2 (en) 2000-10-23 2001-02-07 Enhanced production of safe plasma preparations
US27849601P 2001-03-23 2001-03-23
PCT/US2002/003996 WO2002087560A1 (en) 2001-02-07 2002-02-07 Carboxylic acid such as citric acid for desinfecting or enhacing the production of blood products such as plasma, cryoprecipitate or/and platelet

Publications (1)

Publication Number Publication Date
BR0207058A true BR0207058A (en) 2004-02-17

Family

ID=26959126

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207058-8A BR0207058A (en) 2001-02-07 2002-02-07 Method for reducing transfusion-associated disease and plasma adverse effects to increase the purity and safety of multiple blood-derived components, enriched cryoprecipitate, cryo-depleted plasma, and fibrin glue

Country Status (6)

Country Link
EP (1) EP1363616A1 (en)
AU (1) AU2002248415B8 (en)
BR (1) BR0207058A (en)
CA (1) CA2438223A1 (en)
MX (1) MXPA03007069A (en)
WO (1) WO2002087560A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060019234A1 (en) * 2004-07-22 2006-01-26 Shanbrom Technologies, Llc Modern blood banking employing improved cell preservation composition
US20070049732A1 (en) * 2005-09-01 2007-03-01 Zurlo Eugene J Ultra-high yield intravenous immune globulin preparation
US8835104B2 (en) 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
WO2012139017A1 (en) 2011-04-07 2012-10-11 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates
EP3411383A4 (en) 2016-02-03 2019-08-14 Plasma Technologies, LLC Methods for extracting proteins from a blood-based material
CA3076366C (en) 2017-09-22 2023-05-16 Becton, Dickinson And Company 4% trisodium citrate solution for use as a catheter lock solution
US10815270B1 (en) 2019-09-20 2020-10-27 Plasma Technologies, Llc Compositions and methods for high efficiency protein precipitation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803115A (en) * 1972-05-17 1974-04-09 Baxter Laboratories Inc Stabilization of ahf using heparin
US4086218A (en) * 1975-04-11 1978-04-25 Edward Shanbrom, Inc. Method of preserving blood plasma II
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
US4305871A (en) * 1980-09-02 1981-12-15 Edward Shanbrom Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
US4850993A (en) * 1986-12-22 1989-07-25 Miles Laboratories, Inc. Blood bag system incorporating quinolone carboxylic, acid derivatives
US4977246A (en) * 1989-06-06 1990-12-11 Rorer Pharmaceutical Corporation High recovery process for antihemophilic factor
US4925665A (en) * 1989-06-22 1990-05-15 Thomas Jefferson University Glucose free primary anticoagulant for blood containing citrate ions
US5370869A (en) * 1990-09-04 1994-12-06 Shanbrom; Edward Antimicrobial preservation of platelets and blood factors
US5196428A (en) * 1992-04-03 1993-03-23 Bristol-Myers Squibb Company Imidazo[4,5-b]qinolinyl oxy alkyl ureas
EP0614368A1 (en) * 1992-05-04 1994-09-14 Edward Shanbrom Safe human transfusion blood
JPH09509681A (en) * 1994-12-16 1997-09-30 バクスター、インターナショナル、インコーポレイテッド Control of donor blood characteristics
US6037116A (en) * 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials

Also Published As

Publication number Publication date
AU2002248415B8 (en) 2008-07-24
WO2002087560A1 (en) 2002-11-07
EP1363616A1 (en) 2003-11-26
MXPA03007069A (en) 2004-10-15
AU2002248415B2 (en) 2008-03-20
CA2438223A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
CA2034489A1 (en) Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
BR0113710A (en) Compounds, process for the preparation and use thereof, pharmaceutical composition, process for the treatment and prophylaxis of arthritis, cardiovascular disease, diabetes, renal failure, eating disorders and obesity
HUP9700603A1 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
BR9915553A (en) Anthranilic acid amides and their use as a medicine
IL112572A0 (en) Dexanabinol derivatives and their use as nmda blocking pharmaceutical compositions
AU2001289438A1 (en) Pharmaceutical semi-solid composition of isotretinoin
BR9712523A (en) New heterocyclyl-substituted pyrazole derivatives
BR9916678A (en) Thrombin inhibitors
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
WO2005056585A3 (en) Sars coronavirus s proteins and uses thereof
DE68929388T2 (en) Anticoagulant compound isolated from urine
BR0207058A (en) Method for reducing transfusion-associated disease and plasma adverse effects to increase the purity and safety of multiple blood-derived components, enriched cryoprecipitate, cryo-depleted plasma, and fibrin glue
BR9907025A (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing the same
WO2003051926A3 (en) Anti-cd7 immunotoxin as fusion protein
MXPA01004885A (en) Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers.
BR0007448A (en) Use of a low molecular weight thrombin inhibitor, dialysis solution, dialysis concentrate, kit of parts for use in dialysis, process for preparing a solution, or a concentrate, and method of treatment for dialysis of a patient needing such treatment
WO2005027821A3 (en) Large scale preparation of alpha-1 proteinase inhibitor and use thereof
WO2003047507A3 (en) Factor viii c2 domain variants
WO2004039326A3 (en) Propofol with cysteine
WO2005063219A3 (en) Ibuprofen-containing soft gelatin capsules
ATE338819T1 (en) ANTIGENIC PROTEIN FROM MALASSEZIA
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
WO2003059286A3 (en) Methods and compositions for oxygen transport comprising modified hemoglobin in plasma
WO1998011246A3 (en) ENDO-β-GALACTOSIDASE
BR0007183A (en) Isonipectoamides for the treatment of integrin-mediated disorders

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2094 DE 22/02/2011.